Theratechnologies Secures Final Court Approval For Future Pak Affiliate Transaction

Theratechnologies Inc., a commercial-stage biopharmaceutical company, announced that it has received the final order from the Superior Court of Québec (Commercial Division) approving its previously announced plan of arrangement (the “Arrangement”) with CB Biotechnology, LLC, an affiliate of Future Pak, LLC. This approval follows the endorsement of the Arrangement by Theratechnologies’ shareholders at a special meeting held on September 12, 2025.

The transaction, completed under Chapter XVI – Division II of the Business Corporations Act (Québec), represents the next step in Theratechnologies’ strategic transformation. The Company expects the Arrangement to close on or about September 25, 2025, subject to satisfaction of customary closing conditions.

Future Pak, founded in 1977 and headquartered in Wixom, Michigan, is a privately held contract manufacturer, packager, and distributor of pharmaceutical and nutraceutical products. With operations spanning retail, speciality, and institutional markets, Future Pak brings robust infrastructure and a strong partner network, complementing Theratechnologies’ focus on delivering innovative therapies that aim to redefine standards of care.

Together, the combined expertise of Theratechnologies and Future Pak is expected to strengthen their collective ability to deliver quality-first, patient-centric solutions while expanding commercial opportunities in speciality biopharmaceuticals and manufacturing.